CohBar shareholders will receive a dividend of 3.30 shares of CohBar common stock & pre-merger CohBar shareholders will receive a CVR related to the disposition of any of its assets for 3yrs. The transaction is expected to close in Q3’23
The pre-merger CohBar equity holders will own ~15%; pre-merger Morphogenesis equity holders will own ~77% of the new company on a pro forma basis & investors would own ~9%. The combined company will operate under the name “TuHURA Biosciences, Inc” & will trade on Nasdaq, advancing a personalized cancer vaccine platform & preclinical tumor microenvironment modulator
The P-II/III study of IFx-Hu2.0 is expected to initiate in 2024. CohBar entered into a stock purchase agreement with an affiliate of an investor in Morphogenesis for a $15M private placement to advance the new company’s pipeline, providing a cash runway through 2024
Ref: Globe Newswire | Image: CohBar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
